Adagio Therapeutics company name change
Adagio Therapeutics company name change
Adagio Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based solutions for infectious diseases with pandemic potential. Its lead product candidate was ADG20 (adintrevimab), a neutralizing antibody in Phase 3 clinical trials for the treatment and prevention of COVID-19. The company also had collaborations with Adimab, LLC for antibody discovery and optimization, and with the Scripps Research Institute for identifying vaccine candidates. Adagio Therapeutics was incorporated in 2020 and was based in Waltham, Massachusetts. In September 2022, the company changed its name to Invivyd, Inc. and its stock ticker to IVVD.
ivvd stock forecast 2025
According to the latest forecasts, Invivyd Inc. (IVVD) stock is expected to see significant growth in 2025. Analysts predict that the average price of IVVD will reach $4.5554 by the end of 2025, representing a potential increase of about 230.10% from the current price. The highest price prediction for 2025 is $6.5163, while the lowest estimate is $2.5945. This suggests that IVVD could be a strong buy opportunity for investors looking for high-growth potential in the biotech sector.
ivvd stock news
Invivyd, Inc. (NASDAQ:IVVD)
Invivyd, Inc. (NASDAQ:IVVD) saw its year-to-date share prices rally by 263 percent to end Friday’s trading at $1.61 versus the 44 cents registered last December 31, as investor sentiment continues to be fueled by positive developments from its clinical trials.
On February 5, Invivyd, Inc. (NASDAQ:IVVD)—a pharmaceutical company with a $192.58-million market capitalization—registered its highest price for the year at $2.11, representing a 376-percent surge from December 31’s price, after the company announced that its pipeline candidate, VYD2311, demonstrated promising neutralizing activity against the dominant SARS-CoV-2 variant XEC.
The result further supported the effectiveness of Invivyd, Inc. (NASDAQ:IVVD)’s monoclonal antibodies, including Pemgarda (pemivibart).
Invivyd, Inc. (NASDAQ:IVVD) officially submitted its latest findings to the Food and Drug Administration (FDA), and is expected to update the Pemgarda fact sheet for healthcare providers soon.
Overall IVVD ranks 7th on our list of the top micro and small-cap firms this year so far.
Invivyd, Inc. (NASDAQ:IVVD) saw its year-to-date share prices rally by 263 percent to end Friday’s trading at $1.61 versus the 44 cents registered last December 31, as investor sentiment continues to be fueled by positive developments from its clinical trials.
On February 5, Invivyd, Inc. (NASDAQ:IVVD)—a pharmaceutical company with a $192.58-million market capitalization—registered its highest price for the year at $2.11, representing a 376-percent surge from December 31’s price, after the company announced that its pipeline candidate, VYD2311, demonstrated promising neutralizing activity against the dominant SARS-CoV-2 variant XEC.
The result further supported the effectiveness of Invivyd, Inc. (NASDAQ:IVVD)’s monoclonal antibodies, including Pemgarda (pemivibart).
Invivyd, Inc. (NASDAQ:IVVD) officially submitted its latest findings to the Food and Drug Administration (FDA), and is expected to update the Pemgarda fact sheet for healthcare providers soon.
Overall IVVD ranks 7th on our list of the top micro and small-cap firms this year so far.